Drugs / LY2787106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01340976 | Jan 2010 → Dec 2014 | anemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2787106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01340976 ↗ |
| Action | Inhibit | “Neutralizing hepcidin with a monoclonal antibody” PMID 28327200 ↗ Mar 20171“Hepcidin inhibitor” CHEMBL2109440 ↗ |
| Modality | Monoclonal antibody | “a hepcidin monoclonal antibody” PMID 28327200 ↗ Mar 2017 |
| Route | Intravenous | “Administered IV.” NCT01340976 ↗ |
| Target | HAMP | “Hepcidin inhibitor” CHEMBL2109440 ↗ |